利用核磁共振法探讨类泛素媒介的信息传导分子机制
1. 生物医学科学研究所，台湾 台北 11529；2. 基因体研究中心，台湾 台北 11529；3. 台湾师范大学 物理系，台湾 台北 11677
收稿日期: 2015-02-11
修回日期: 2015-05-09
网络出版日期: 2015-06-05
Probing the Molecular Basis of SUMO-Mediated Signaling Pathway by NMR
1. Institute of Biomedical Sciences, Taipei 11529, China; 2. Genomics Research Center, Taipei 11529, China; 3. Department of Physics, Taiwan Normal University, Taipei 11677, China
Received date: 2015-02-11
Revised date: 2015-05-09
Online published: 2015-06-05
转译后类泛素修饰调控多项细胞活动，此信息传导的途径为：第一步将类泛素(SUMO)接于E1 活化蛋白，第二步将SUMO 转移到E2 共轭蛋白(Ubc9)，然后帮助受体蛋白完成类泛素化，最后借由蛋白酶去除类泛素完成整个传导过程．受体蛋白的类泛素化调控基本上靠Ubc9 来辨识受体蛋白上的特殊类泛素序列(SM)，在某些情况下亦可借由E3 辨识完成．而类泛素辨识序列功效的发挥则依赖于招慕含有类泛素辨识序列(SIM)的感应蛋白来实现．此外原核细胞的类泛素化皆有形成多聚类泛素(poly-SUMO)化的能力．多聚类泛素化修饰可被含多聚类泛素辨识序列(poly-SIM)的蛋白质如RNF4 识别，促进受体蛋白的多聚类泛素化，并导致目标蛋白的分解．该文综述了作者所在研究组近年来利用核磁共振法研究类泛素介导的信息传导分子机制方面的成果．
黄太煌 . 利用核磁共振法探讨类泛素媒介的信息传导分子机制[J]. 波谱学杂志, 2015 , 32(2) : 163 -180 . DOI: 10.11938/cjmr20150203
Post-translational modification by Small Ubiquitin-like MOdifier (SUMO) proteins regulates a diverse array of cellular events. The signaling process is initiated by attaching SUMO to the E1 activating protein. In the second step SUMO is transferred to E2 conjugating protein (Ubc9). Lastly, Ubc9 couples SUMO to a target substrate covalently. The process is terminated by protease removal of SUMOs from the substrates. Sumoylation is regulated primarily through specific recognition of the sumoylation motif (SM) by Ubc9 and, in some cases, by E3-substrate recognition. The functional consequences of SUMO modification are mostly mediated by recruitment of effector proteins that contain a SUMO Interaction Motif (SIM). Furthermore, SUMO can form poly-SUMO conjugate, which can be recognized by proteins containing poly-SIMs, such as the RING-finger 4 (RNF4) ubiquitin E3 ligase. RNF4 contains four SIMs that
facilitate poly-SUMO-specific ubiquitination and targets poly-sumoylated proteins for degradation. Here we review NMR structure-functional studies, conducted in our laboratory and aimed at dissecting the molecular basis of SUMO-mediated pathway.
[1] Pickart C M. Mechanisms underlying ubiquitination[J]. Annu Rev Biochem, 2001, 70: 503－533.
[2] Gareau J R, Lima C D. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition[J]. Nat Rev Mol Cell Bio, 2010, 11: 861－871.
[3] Hay R T. Decoding the SUMO signal[J]. Biochem Soc Trans, 2013, 41: 463－473.
[4] Matic I, van Hagen M, Schimmel J, et al. In vivo identification of human SUMO polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy[J]. Mol Cell Proteomics, 2007, 7: 132－144.
[5] Cheng C H, Lo Y H, Liang S S, et al. SUMO modifications control assembly of synaptonemal complex and polycomplex in meiosis of Saccharomyces cerevisiae[J]. Genes Dev, 2006, 20: 2 067－2 081.
[6] Schwartz D C, Felberbaum R, Hochstrasser M. The Ulp2 SUMO protease is required for cell division following termination of the DNA damage checkpoint[J]. Mol Cell Biol, 2007, 27: 6 948－6 961.
[7] Rodriguez M S, Dargemont C, Hay R T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting[J]. J Biol Chem, 2001, 276: 12 654－12 659.
[8] Sampson D A, Wang M, Matunis M J. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification[J]. J Biol Chem, 2001, 276: 21 664－21 669.
[9] Meroni G. Genomics and evolution of the TRIM gene family[J]. Adv Exp Med Biol, 2012, 770: 1－9.
[10] Bernardi R, Pandolfi P P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies[J]. Nat Rev Mol Cell Biol, 2007, 8: 1 006－1 016.
[11] Jensen K, Shiels C, Freemont P S. PML protein isoforms and the RBCC/TRIM motif[J]. Oncogene Research, 2001, 20: 7 223－7 233.
[12] Carracedo A, Ito K, Pandolfi P P. The nuclear bodies inside out: PML conquers the cytoplasm[J]. Curr Opin Cell Biol, 2011, 23: 360－366.
[13] Lallemand-Breitenbach V, Zhu J, Puvion F, et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11s proteasome recruitment, and as2O3-Induced PML or PML/Retinoic acid receptor α degradation[J]. J Exp Med, 2001, 193: 1 361－1 371.
[14] Duprez E, Saurin A J, Desterro J M, et al. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation[J]. J Cell Sci, 1999, 112(Pt 3): 381－393.
[15] Chu Y, Yang X. SUMO E3 ligase activity of TRIM proteins[J]. Oncogene, 2011, 30: 1 108－1 116.
[16] Huang S Y, Chang C F, Fang P J, et al. The RING domain of human promyelocytic leukemia protein (PML)[J]. J Biomol NMR, 2015, 61: 173－180.
[17] Huang S Y, Naik M T, Chang C F, et al. NMR structure note: The B-box 1 dimer of human promyelocytic leukemia protein[J]. J Biomol NMR, 2014, 60: 275－281.
[18] Borden K L, Boddy M N, Lally J, et al. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML[J]. EMBO J, 1995, 14: 1 532－1 541.
[19] Flotho A, Melchior F. Sumoylation: a regulatory protein modification in health and disease[J]. Annu Rev Biochem, 2013, 82: 357－385.
[20] Bernier-Villamor V, Sampson D A, Matunis M J, et al. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1[J]. Cell, 2002, 108: 345－356.
[21] Salomoni P, Khelifi A F. Daxx: death or survival protein[J]? Trends Cell Biol, 2006, 16: 97－104.
[22] Shih H M, Chang C C, Kuo H Y, et al. Daxx mediates SUMO-dependent transcriptional control and subnuclear compartmentalization[J]. Biochem Soc T, 2007, 35: 1 397－1 400.
[23] Croxton R, Puto L A, de Belle I, et al. Daxx represses expression of a subset of antiapoptotic genes regulated by nuclear factor-kappa B[J]. Cancer Res, 2006, 66: 9 026－9 035.
[24] Torii S, Egan D A, Evans R A, et al. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs)[J]. Embo J, 1999, 18: 6 037－6 049.
[25] Lin D -Y, Huang Y -S, Jeng J -C, et al. Role of SUMO-interacting motif in daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors[J]. Mol Cell, 2006, 24: 341－354.
[26] Chang C C, Naik M T, Huang Y S, et al. Structural and functional roles of Daxx SIM phosphorylation in SUMO paralog-selective binding and apoptosis modulation[J]. Mol Cell, 2011, 42: 62－74.
[27] Olsten M E, Litchfield D W. Order or chaos? an evaluation of the regulation of protein kinase CK2[J]. Biochem Cell Biol, 2004, 82: 681－693.
[28] Matic I, van Hagen M, Schimmel J, et al. In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy[J]. Mol Cellular Proteomics, 2008, 7: 132－144.
[29] Poulsen S L, Hansen R K, Wagner S A, et al. RNF111/Arkadia is a SUMO-targeted ubiquitin ligase that facilitates the DNA damage response[J]. J Cell Biol, 2013, 201: 797－807.
[30] Tatham M H, Geoffroy M C, Shen L, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation[J]. Nature Cell Biol, 2008, 10: 538－546.
[31] Plechanovova A, Jaffray E G, Tatham M H, et al. Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis[J]. Nature, 2012, 489: U115－U135.
[32] Bruderer R, Tatham M H, Plechanovova A, et al. Purification and identification of endogenous polySUMO conjugates[J]. EMBO Rep, 2011, 12: 142－148.
[33] Sun H Y, Hunter T. Poly-small ubiquitin-like modifier (PolySUMO)-binding proteins identified through a string search[J]. J Biol Chem, 2012, 287: 42 071－42 083.
[34] Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway[J]. Nat Cell Biol, 2008, 10: 547－555.
[35] Keusekotten K, Bade V N, Meyer-Teschendorf K, et al. Multivalent interactions of the SUMO-interaction motifs in RING-finger protein 4 (RNF4) determine the specificity for chains of the small ubiquitin-related modifier (SUMO)[J].
Biochem J, 2014, 457(1): 207－214.
[36] Kung C C, Naik M T, Wang S H, et al. Structural analysis of poly-SUMO chain recognition by the RNF4-SIMs domain[J]. Biochem J, 2014, 462: 53－65.
[37] Wishart D S, Case D A. Use of chemical shifts in macromolecular structure determination[J]. Methods Enzymol, 2001, 338: 3－34.
[38] Tamiola K, Mulder F A A. Using NMR chemical shifts to calculate the propensity for structural order and disorder in proteins[J]. Biochem Soc T, 2012, 40: 1 014－1 020.
[39] Rambo R P, Tainer J A. Super-resolution in solution X-ray scattering and its applications to structural systems biology[J]. Ann Rev Biophys, 2013, 42(42): 415－441.
[40] Bernado P, Mylonas E, Petoukhov M V, et al. Structural characterization of flexible proteins using small-angle X-ray scattering[J]. J Am Chem Soc, 2007, 129: 5 656－5 664.
/
| 〈 |
|
〉 |